SEP 06, 2016 6:30 PM PDT

Immune Biomarkers for Idiopathic Pulmonary Fibrosis

WRITTEN BY: Kara Marker
There’s no cure for idiopathic pulmonary fibrosis (IPF), and the disease gets irreversibly worse as it progresses. As scientists frantically look for biomarkers to catch the disease early and begin treating symptoms, a new study shows that biomarkers for IPF may be the same as those for some types of cancer.
Staining of surface molecules (CD11 in red, CD33 in green) on cells in lung tissue, nuclei in blue. MDSC are positive for both surface markers and consequently appear orange (arrow).
For people with IPF, usually older adults, their lung tissue becomes increasingly scarred over time. On average, people with IPF only live about three to five years after their diagnosis. Cause of death usually comes from respiratory failure, pulmonary hypertension, heart failure, pulmonary embolism, pneumonia, or lung cancer. Medical professionals believe that although the disease seems to be incurable, identifying patients as early as possible will give them the best chance of living longer and have a fuller life.

From the German Research Center for Environmental Health in a study published in the European Respiratory Journal, scientists discovered a connection between myeloid-derived suppressor cells (MDSCs) in the blood and incidence of IPF. The higher the number of MDSCs, the more limited the lung function IPF patients had.

“MDSC are primarily found in fibrotic niches of IPF lungs characterized by increased interstitial tissue and scarring, that is, in regions where the disease is very pronounced,” said Professor Oliver Eickelberg, study leader.

MDSCs are capable of suppressing the T cell response, an ability that is helpful in regulating the immune response but not desirable in cases of cancer or infection. High levels of MDSC activity are known to contribute to a poor prognosis in certain instances of cancer, and Eickelberg’s team seemed to be on the verge of discovering a similar contribution in cases of IPF.

Eickelberg and his team looked at blood samples of 170 study participants, with almost half being IPF patients. They analyzed the samples, looking for lymphocytes like MDSCs that could be linked to IPF in some way. After successfully identifying a significantly higher count of MDSCs in IPF patients versus health control patients, the researchers also saw an inverse relationship existing between lung function and levels of circulating MDSCs. However, the relationship appears to be unique to IPF patients; no inverse correlation was found in patients with chronic obstructive pulmonary disease (COPD) or other interstitial lung diseases.

The researchers also measured gene activity common in immune cells, and found that immune-associated genes were expressed less frequently in blood samples with high levels of MDSCs. Observing human lung tissue from IPF patients also provided evidence supporting their claim that MDSCs were compromising the immune system, exacerbating cases of IPF.

Next, the team plans to determine how the presence of MDSCs in high quantities in the blood can be used as a biomarker for IPF, looking at how soon IPF could be diagnosed based on MDSC presence. Additionally, researchers will explore the possibility of suppressing accumulation of MDSCs as a potential treatment option for IPF.
 


Sources: National Heart, Lung, and Blood Institute, Nature Reviews ImmunologyHelmholtz Zentrum München
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 18, 2021
Cancer
The History of Immunotherapy: Toxins, Targets & T Cells
OCT 18, 2021
The History of Immunotherapy: Toxins, Targets & T Cells
Cancer immunotherapy, a treatment that directly enhances a patient’s immune system, is typically perceived as a mo ...
OCT 26, 2021
Immunology
Two Different Arms, Twice the Cancer-Killing Potential?
OCT 26, 2021
Two Different Arms, Twice the Cancer-Killing Potential?
Our immune system has developed an arsenal of sophisticated molecular weapons to defend us against the continuous barrag ...
OCT 19, 2021
Drug Discovery & Development
Researchers develop a potent antiviral drug for dengue fever
OCT 19, 2021
Researchers develop a potent antiviral drug for dengue fever
Dengue fever is a mosquito borne illness that is widespread, especially in tropical countries. The global incidence of d ...
NOV 01, 2021
Cell & Molecular Biology
How SARS-CoV-2 Evades Antiviral Defenses
NOV 01, 2021
How SARS-CoV-2 Evades Antiviral Defenses
Researchers have learned a lot about the SARS-CoV-2 virus since the start of the COVID-19 pandemic. We know that he viru ...
NOV 05, 2021
Cancer
The Labroots 2021 Cancer Research and Oncology Virtual Event Poster Winner
NOV 05, 2021
The Labroots 2021 Cancer Research and Oncology Virtual Event Poster Winner
Every year, Labroots hosts an exciting series of Virtual Events that focus on various scientific topics. These virtual m ...
NOV 18, 2021
Immunology
Ultrasound Helps Shuttle Cancer-Killing Antibodies to the Brain
NOV 18, 2021
Ultrasound Helps Shuttle Cancer-Killing Antibodies to the Brain
Antibody therapies harness the immune system's power to fight a broad spectrum of diseases, from cancer to infectiou ...
Loading Comments...